One of the easiest ways to get kids hooked on reading is to get them into a great book series. All it takes is a captivating Book 1, and they're off and running. Fantasy, mystery, science fiction, ...

for the treatment of adult patients with generalized myasthenia gravis or gMG who are anti-acetylcholine receptor or AChR antibody positive and adult patients with chronic inflammatory ...

for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

Last week­end, re­searchers gath­ered in San Diego for the Amer­i­can Acad­e­my of Neu­rol­o­gy’s an­nu­al meet­ing to dis­cuss the lat­est ad­vance­ments and clin­i­cal tri­ ...

Its commercial products include Zejula for ovarian cancer, VYVGART for myasthenia gravis, and NUZYRA for bacterial infections, among others. Headquartered in Shanghai, China, Zai Lab collaborates ...

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: ...

SAN DIEGO — Inebilizumab (Uplizna, Amgen) is safe and effective up to 52 weeks in patients with generalized myasthenia gravis (MG), new research suggested. If approved, the drug would ...

SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis. Amgen’s anti-CD19 antibody Uplizna ...

Chinese biotech RemeGen (SHA: 688331) has reported positive late-stage clinical trial data for its dual-target fusion protein telitacicept in patients with generalized myasthenia gravis, offering a ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...